These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 1956763)

  • 1. Standardization of definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting.
    Benichou C; Solal Celigny P
    Nouv Rev Fr Hematol (1978); 1991; 33(3):257-62. PubMed ID: 1956763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced cytopenia.
    Int J Clin Pharmacol Ther Toxicol; 1991 Feb; 29(2):75-81. PubMed ID: 2026468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting.
    Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):317-22. PubMed ID: 2272712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [International reporting of adverse drug reactions. Final report of CIOMS ADR Working Group].
    Royer RJ; Benichou C
    Therapie; 1991; 46(3):173-8. PubMed ID: 1792648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Criteria of drug-induced liver disorders. Report of an international consensus meeting.
    Bénichou C
    J Hepatol; 1990 Sep; 11(2):272-6. PubMed ID: 2254635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Criteria for assessing granulocytic or platelet cytopenia caused by drugs. Results of consensus meetings].
    Solal-Céligny P; Benichou C; Boivin P; Castot A; Coulombel L; Danan G; Degos L; Evreux JC; Lagier G; Lavarenne J
    Nouv Rev Fr Hematol (1978); 1987; 29(4):265-70. PubMed ID: 3320952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International reporting on adverse drug reactions: the CIOMS project. CIOMS ADR Working Group.
    Faich GA; Castle W; Bankowski Z
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):133-8. PubMed ID: 2338366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunologic and drug-induced dyshematopoiesis (author's transl)].
    Huhn D
    MMW Munch Med Wochenschr; 1980 Aug; 122(35):1179-83. PubMed ID: 6450890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XIII): clinical pathology and general disorders.
    Council for International Organization of Medical Sciences
    Pharmacoepidemiol Drug Saf; 1999 May; 8(3):217-24. PubMed ID: 15073931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definitions and basic requirements for the use of terms for reporting adverse drug reactions (X): gastrointestinal system disorders.
    Pharmacoepidemiol Drug Saf; 1998 Jul; 7(4):281-7. PubMed ID: 15073991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematologic side effects of drugs.
    Lubran MM
    Ann Clin Lab Sci; 1989; 19(2):114-21. PubMed ID: 2665627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitions of terms for reporting adverse drug reactions (IX): nervous system and psychiatric disorders.
    Council for International Organizations of Medical Sciences
    Pharmacoepidemiol Drug Saf; 1998 Jan; 7(1):39-49. PubMed ID: 15073745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XII): collagen disorders and musculo-skeletal disorders.
    Council for International Organizations of Medical Sciences
    Pharmacoepidemiol Drug Saf; 1999 Mar; 8(2):141-5. PubMed ID: 15073939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Definitions and basic requirements for the use of terms for reporting adverse drug reactions (XI): cardiovascular system disorders.
    Bankowski Z
    Pharmacoepidemiol Drug Saf; 1998 Sep; 7(5):351-7. PubMed ID: 15073983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic reactions to carbonic anhydrase inhibitors.
    Fraunfelder FT; Meyer SM; Bagby GC; Dreis MW
    Am J Ophthalmol; 1985 Jul; 100(1):79-81. PubMed ID: 4014383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic requirements for the use of terms for reporting adverse drug reactions (VIII): renal and urinary system disorders.
    Council for International Organizations of Medical Sciences
    Pharmacoepidemiol Drug Saf; 1997 May; 6(3):203-11. PubMed ID: 15073789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the prevalence of myelodysplastic syndromes in patients with unexplained cytopenias: a retrospective study of 322 bone marrows.
    Buckstein R; Jang K; Friedlich J; Zhang L; Reis M; Chesney A; Wells RA
    Leuk Res; 2009 Oct; 33(10):1313-8. PubMed ID: 19282029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Differential diagnosis of hemocytopenia syndromes].
    Germanov VA; Elizarova NA
    Probl Gematol Pereliv Krovi; 1978 Dec; (12):6-10. PubMed ID: 746038
    [No Abstract]   [Full Text] [Related]  

  • 19. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow aplasia--a rare complication of imatinib therapy in CML patients.
    Srinivas U; Pillai LS; Kumar R; Pati HP; Saxena R
    Am J Hematol; 2007 Apr; 82(4):314-6. PubMed ID: 17013815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.